Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 1, 2011, Pages 55-62

  Chang, Yan ^a   Fang, Wenfang B ^a   Lin, Shen Nan ^a   Moody, David E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 1,5 DIMETHYL 3,3 DIPHENYLPYROLIDINE; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DILTIAZEM; DRUG METABOLITE; ERYTHROMYCIN; FLUOXETINE; ISONIAZID; KETOCONAZOLE; METHADONE; MIDAZOLAM; MONOCLONAL ANTIBODY; PYRROLIDINE DERIVATIVE; RALOXIFENE; TAMOXIFEN; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY;

ANALGESICS, OPIOID; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METHADONE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; STEREOISOMERISM;

EID: 78650221496     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00628.x     Document Type: Article

References (35)

1. Kristensen K, Christensen CB, Christrup LL. The mu1, mu 2, delta, kappa opioid receptor binding properties of methadone stereoisomers and morphine. Life Sci 1995;56:45-50.
2. Scott CC, Robbins EB, Chen KK. Pharmacological comparison of the optical isomers of methadone. J Pharmacol Exp Ther 1948;92:282-6.
3. Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996;18:221-7.
4. Foster DJR, Somogyi AA, Dyer KR, White JM, Bocher F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000;50:427-40.
5. Moody DE, Lin SN, Chang Y, Lamm L, Greenwald MK, Ahmed MS. An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes. J Anal Toxicol 2008;32:208-19.
6. Kreek MJ. Drug interactions with methadone. Ann NY Acad Sci 1976;281:350-71.
7. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-93.
8. Ferrari A, Coccia CPR, Bertolini A, Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9.
9. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
10. Eap CB, Crettol S, Rougier JS, Schlapfer J, Grilo LS, Deglon JJ et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28.
11. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
12. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A in the N-demethylation of l-α-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab Dispos 1997;25:1347-53.
13. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-12.
14. Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes™): Application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 2003;24:2577-87.
15. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003;31:742-7.
16. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16:36-44.
17. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69.
18. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389-99.
19. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363-74.
20. Neff JA, Moody DE. Differential N-demethylation of l-α-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 2001;284:751-6.
21. Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelboin HV. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos 1999;27:102-9.
22. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between approaches. Drug Metab Dispos 2000;28:1493-504.
23. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000;49:343-51.
24. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004;308:189-97.
25. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004;32:626-31.
26. Walsky RL, Obach RS. A comparison of 2-phenyl-2-(1-piperidinyl)propane (PPP), 1, 1', 1''-phosphinothioylidynetrisaziridine (ThioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 2007;35:2053-9.
27. Ekins S, VandenBranden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997;7:165-79.
28. Guo Z, Raeissi S, White RB, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997;25:390-3.
29. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604.
30. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81.
31. Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009;67:29-37.
32. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-34.
33. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008;84:497-505.
34. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport. Anesthesiology 2009;110:660-72.
35. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-9.